Please login to the form below
Interim analysis
This page shows the latest Interim analysis news and features for those working in and with pharma, biotech and healthcare.
Pfizer’s RSV vaccine candidate for older adults backed by FDA Advisory Committee
The study showed the vaccine was 85.7% effective among participants with three or more symptoms, and 66.7% for two or more symptoms, according to an interim analysis carried out
Latest news
-
Janssen reports updated phase 3 results for niraparib combination in prostate cancer
The second interim analysis of the study, which will be presented at this year’s American Society of Clinical Oncology’s Genitourinary Cancers Symposium, continues to demonstrate improved outcomes in the ... Updated radiographic progression-free
-
Genentech reports positive phase 3 data for its Tecentriq combination in liver cancer
The pre-specified interim analysis of the IMbrave050 study showed that Tecentriq in combination with Avastin (bevacizumab) significantly improved RFS in HCC patients with an increased risk of recurrence following resection ... Overall survival data was
-
Takeda therapy shows promise in rare blood clotting disorder
Results from a pre-planned interim analysis of the phase 3 trial showed TAK-755 reduced the incidence of thrombocytopenia events by 60%, an important marker of disease activity in cTTP,
-
Pfizer’s RSV vaccine candidate accepted for FDA priority review for use in older adults
The study showed the vaccine was 85.7% effective among participants with three or more symptoms, and 66.7% for two or more symptoms, according to an interim analysis carried out ... to an interim analysis from the phase 3 MATISSE trial.
-
GSK’s Jemperli shows promise in phase 3 endometrial cancer trial
An interim analysis noted the trial met its primary endpoint of progression-free survival. ... GSK has announced positive results from a planned interim analysis of part one of its phase 3 RUBY trial, investigating Jemperli (dostarlimab) in the treatment
More from news
Approximately 0 fully matching, plus 202 partially matching documents found.
Latest Intelligence
-
Treatment and prevention of cardiovascular disease
By contrast, the recent STRENGTH trial (Statin Residual Risk Reduction with EpaNova in High Cardiovascular Risk Patients with Hypertriglyceridemia) ‘was terminated early due to interim analysis revealing low probability for benefit
-
Assessing the value of interim analyses in clinical trials
When to conduct an interim analysis. The timing, frequency and methods for the analysis should always be specified in the trial protocol before the study starts. ... benefits of the interim analysis, in terms of cost savings or the safety of the subjects,
-
Key considerations for disease- modifying Parkinson’s disease trials
For instance, initiate a study with multiple doses, then remove inefficacious or intolerable dosage levels, and/or adjust patient numbers in different dosage groups based on interim analysis.
-
Oncology drugs under AMNOG: part two
of Xalkori, below - the drug can achieve accelerated approval on the basis of an interim analysis or phase II data before OS is established. ... However, the company was able to submit a re-analysis of morbidity and quality of life data.
-
Interview: Yoshihiko Hatanaka, CEO and president, Astellas
from an interim analysis in men with advanced prostate cancer previously treated with chemotherapy.
More from intelligence
Approximately 1 fully matching, plus 4 partially matching documents found.
Latest appointments
-
Kiadis Pharma appoints Vincent Brichard to supervisory board
Atir achieved some extremely compelling clinical data and the phase II study interim analysis in December demonstrated the drug's true potential as an adjunctive life-saving therapy for blood cancer
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
Is your clinical trial method tried and tested with patients in mind?
added or removed, based on pre-defined interim analysis periods, and real-time decisions based on incoming data rather than waiting until the final analysis.
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- Strategy Director - Healthcare Advertising
- £90,000 - £120,000 yearly
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- £100,000 - £115,000 yearly
-
Technical Sales Representative
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
- FDA proposes improvements for oncology clinical trials supporting accelerated approval
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- AstraZeneca’s mild combination asthma reliever approved in UK
- Eli Lilly increases investment to almost $1bn for new Irish manufacturing facility
- Merck reports positive results for Keytruda plus chemotherapy in endometrial cancer
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- Bristol Myers Squibb’s Sotyktu approved by EC for plaque psoriasis
- Positive results for Almirall’s lebrikizumab in atopic dermatitis published in NEJM and BJD
- When to call in the specialists: strategy in Medical Affairs
- Time to talk about health inequalities
- Powering Rapid Cognitive Analysis with AI
- AstraZeneca and Amgen’s Tezspire recommended by NICE for severe asthma
PMHub
Langland
Langland, a Publicis Health company, is the only health communications agency that thinks further across Clinical Trial Experience, Medical Strategy...
Latest intelligence
- Time to talk about health inequalities
- Health inequalities are increasingly being recognised as a crucial healthcare challenge in the UK...
- The speed of science and the pace of comms
- Pharma red tape slows comms but there is a solution, Paul Hutchings, founder of fox&cat, writes....
- Improving cardiovascular disease care and awareness
- Scott Curley talks to PME about the risks of CVD and the importance of getting the right treatment at the right time...
